MUMBAI - India's top generic drug maker, Cipla, is speeding up its entry into biosimilars with the newly named Biomab, an equal stake joint venture with an undisclosed Chinese company
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.
